David Resnick is the team leader of the Patent group and he works with startup and established companies, as well as major U.S. research institutions, to develop comprehensive patent strategies to protect their intellectual property.
My practice is focused on strategic portfolio management, patent prosecution, transactional matters and associated client counseling. I manage the patent portfolios of some of the leading U.S. research institutions and domestic and international corporations. I also represent some of the world’s most recognized life sciences corporations before the U.S. Patent and Trademark Office. I have extensive experience in the life sciences and have particular experience in the areas of pharmacogenomics, proteomics and disease biomarkers and their application in the evolving field of personalized medicine.
I’ve written articles on patent prosecution practice, personalized medicine and technology issues for Nature Biotechnology, The Journal of Biolaw & Business, Personalized Medicine and other publications. I’m also a member of the editorial board of Pharmaceutical Patent Analyst.
I regularly assist clients in building and evaluating their intellectual property portfolios as well as in evaluating the intellectual property held by competitors. I regularly conduct freedom-to-operate analyses and prepare infringement and validity opinions involving complex and cutting-edge technologies.
I assist clients with patent prosecution in the areas of:
I work closely with my clients to identify and analyze acquisition targets and regularly conduct due diligence related to potential acquisitions.
In the aftermath of the Prometheus decision, and until such time as further judicial decisions provide greater clarity, I foresee that many life sciences companies will continue to struggle with respect to what qualifies as patent-eligible subject matter.
NBC Boston & New England Cable News | January 27, 2017
This media clip highlights the Wheelchair Man book launch party hosted at the Nixon Peabody Boston office and features pro bono client, Mohammed Sayed (AKA Wheelchair Man). Boston IP counseling & transactions partner David Resnick and public company transactions associate Tevia Pollard helped Mohammed create his new non-profit RimPower.
Boston Globe | October 07, 2016
Boston Intellectual Property partner David Resnick is mentioned in this article as legal counsel to Mohammad Sayed, a young inventor from Afghanistan who is developing adaptive products and a comic book series to inspire people with disabilities and to raise awareness in cultures that keep disabled individuals hidden from view. Boston Public Company Transactions associate Tevia Pollard and Labor & Employment associate Matt Frankel work with David on this pro bono matter.
Law360 | January 08, 2015
Boston IP Counseling & Transactions partner David Resnick is quoted in this article discussing potential challenges facing those applying for new types of marijuana plant patents from the U.S. Patent and Trademark Office.
Patent Law Alert | 05.19.17
Patent Law Alert | 04.26.17
Intellectual Property Alert | 09.21.15
Intellectual Property Alert | 08.21.15
Syracuse University School of Law, J.D.
University of Rhode Island, M.S., Microbiology
University of Rhode Island, B.S., Microbiology
U.S. District Court, District of Massachusetts
U.S. Court of Appeals, Federal Circuit
U.S. Patent and Trademark Office
David has been selected by his peers for inclusion in The Best Lawyers in America© 2017 for Biotechnology Law and Patent Law in Boston, MA. He has been listed in Best Lawyers since 2015.
David is recognized by IAM Patent 1000 as one of the world’s leading patent practitioners.
In 2013 and 2014, David was recognized as an “IP Star” by Managing Intellectual Property. Additionally, he was recognized as a “Life Sciences Star” by LMG Life Sciences in 2012 and 2013. David was also recognized by Super Lawyers in 2013.
David is a member of the Association of University Technology Managers and the American Intellectual Property Law Association. David is also a member of the Personalized Medicine Coalition’s Public Policy Committee.